Compare · HAE vs MDLN
HAE vs MDLN
Side-by-side comparison of Haemonetics Corporation (HAE) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAE and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 13.0x HAE ($3.40B).
- Over the past year, HAE is up 4.6% and MDLN is down 17.1% - HAE leads by 21.6 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 15 for HAE).
- Both have 25 recent analyst ratings on file.
- Company
- Haemonetics Corporation
- Medline Inc.
- Price
- $74.91+4.86%
- $33.80+0.58%
- Market cap
- $3.40B
- $44.40B
- 1M return
- +37.96%
- -19.55%
- 1Y return
- +4.58%
- -17.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- 2025
- News (4w)
- 15
- 20
- Recent ratings
- 25
- 25
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Latest HAE
- VP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 259 shares, decreasing direct ownership by 4% to 6,242 units (SEC Form 4) (tax withholding)
- SVP, Human Resources Miller Laurie A. covered exercise/tax liability with 313 shares, decreasing direct ownership by 0.76% to 40,987 units (SEC Form 4) (for withholding tax)
- Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Haemonetics Updates Financial Reporting Segments
- Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by Haemonetics Corporation
- Haemonetics upgraded by BofA Securities with a new price target
- SEC Form 10-K filed by Haemonetics Corporation
- EVP and General Counsel Basil Michelle L covered exercise/tax liability with 2,913 shares and was granted 28,424 shares, increasing direct ownership by 59% to 68,829 units (SEC Form 4) (tax withholding)
- EVP, Chief Operating Officer Chan Frank was granted 27,535 shares and covered exercise/tax liability with 546 shares, increasing direct ownership by 454% to 32,936 units (SEC Form 4) (tax withholding)
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)